SPECC1 as a pan-cancer biomarker: unraveling its role in drug sensitivity and resistance mechanisms
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
SPECC1 as a pan-cancer biomarker: unraveling its role in drug sensitivity and resistance mechanisms ; volume:15 ; number:1 ; day:13 ; month:10 ; year:2024 ; pages:1-14 ; date:12.2024
Discover oncology ; 15, Heft 1 (13.10.2024), 1-14, 12.2024
- Urheber
-
Liu, Dongwei
Wang, Xidi
Cui, Lingfei
Zhang, Mingxia
Lei, Kefeng
Aierken, Nijiati
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s12672-024-01426-x
- URN
-
urn:nbn:de:101:1-2412312108245.424374297425
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:38 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Liu, Dongwei
- Wang, Xidi
- Cui, Lingfei
- Zhang, Mingxia
- Lei, Kefeng
- Aierken, Nijiati
- SpringerLink (Online service)
Ähnliche Objekte (12)
Pan-cancer analysis identifies BIRC5 as a prognostic biomarker
NEK2 is a potential pan-cancer biomarker and immunotherapy target
Pan-cancer analysis of COL15A1: an immunological and prognostic biomarker
Systematic pan-cancer analysis identifies ZBTB11 as a potential pan-cancer biomarker and immunotherapy target in multiple tumor types
Human pan-cancer analysis of the predictive biomarker for the CDKN3
CISD3 is a prognostic biomarker and therapeutic target in pan-cancer
MCM10, a potential diagnostic, immunological, and prognostic biomarker in pan-cancer
Pan-cancer molecular tumor board experience with biomarker-driven precision immunotherapy
SLMO2 is a potential prognostic and immunological biomarker in human pan-cancer
Comprehensive pan-cancer analysis of STAT3 as a prognostic and immunological biomarker
PRKCSH serves as a potential immunological and prognostic biomarker in pan-cancer
Pan-cancer analysis identifies RNF43 as a prognostic, therapeutic and immunological biomarker
Pan-cancer analysis identifies BIRC5 as a prognostic biomarker
NEK2 is a potential pan-cancer biomarker and immunotherapy target
Pan-cancer analysis of COL15A1: an immunological and prognostic biomarker
Systematic pan-cancer analysis identifies ZBTB11 as a potential pan-cancer biomarker and immunotherapy target in multiple tumor types
Human pan-cancer analysis of the predictive biomarker for the CDKN3
CISD3 is a prognostic biomarker and therapeutic target in pan-cancer
MCM10, a potential diagnostic, immunological, and prognostic biomarker in pan-cancer
Pan-cancer molecular tumor board experience with biomarker-driven precision immunotherapy
SLMO2 is a potential prognostic and immunological biomarker in human pan-cancer
Comprehensive pan-cancer analysis of STAT3 as a prognostic and immunological biomarker
PRKCSH serves as a potential immunological and prognostic biomarker in pan-cancer
Pan-cancer analysis identifies RNF43 as a prognostic, therapeutic and immunological biomarker
Pan-cancer analysis identifies BIRC5 as a prognostic biomarker
NEK2 is a potential pan-cancer biomarker and immunotherapy target
Pan-cancer analysis of COL15A1: an immunological and prognostic biomarker
Systematic pan-cancer analysis identifies ZBTB11 as a potential pan-cancer biomarker and immunotherapy target in multiple tumor types
Human pan-cancer analysis of the predictive biomarker for the CDKN3
CISD3 is a prognostic biomarker and therapeutic target in pan-cancer
MCM10, a potential diagnostic, immunological, and prognostic biomarker in pan-cancer
Pan-cancer molecular tumor board experience with biomarker-driven precision immunotherapy
SLMO2 is a potential prognostic and immunological biomarker in human pan-cancer
Comprehensive pan-cancer analysis of STAT3 as a prognostic and immunological biomarker
PRKCSH serves as a potential immunological and prognostic biomarker in pan-cancer